The United States Patent and Trademark Office (USPTO) has granted patent US12582728B2, titled 'Theranostic agents for PSMA positive cancers,' to Memorial Sloan Kettering Cancer Center. The patent, effective March 24, 2026, covers novel radiohalogenated PSMA targeting agents and their use in diagnostic imaging and radiation therapy for PSMA-positive cancers. The application was filed on August 28, 2020, under application number 17638512, and includes 19 claims.

This patent grant is primarily an intellectual property event and does not impose new direct compliance obligations on regulated entities. However, it may impact companies involved in the development, manufacturing, or commercialization of cancer diagnostics and therapeutics, particularly those utilizing PSMA-targeting agents. Companies operating in this space should be aware of the patented technology to ensure freedom to operate and to identify potential licensing opportunities or competitive landscapes. No specific compliance deadlines or penalties are associated with this patent grant itself.